




Torsten Almén



Did you know?

The open seas were the inspiration behind the evolution of iodinated contrast media


Inspired by a swim in the sea, the Swedish radiologist Torsten Almén set out to reduce the osmolality of iodinated contrast media (CM), championing the evolution from...

1960s

**high-osmolar
CM (HOCM)...**

Diatrizoate

- Osmolality: 1940–2140 mOsm/kg H₂O¹
- Iodine atoms/particles in solution: 3/2¹




1980s

**...to low-osmolar
CM (LOCM)...**

Iohexol

- Osmolality: 640-780 mOsm/kg H₂O¹
- Iodine atoms/particles in solution: 3/1¹




1993

**...and ultimately, to iso-osmolar
Visipaque (iodixanol)**

Visipaque (iodixanol)


- Osmolality: 290 mOsm/kg H₂O¹
- Iodine atoms/particles in solution: 6/1¹



VISIPAQUE™
(IODIXANOL) INJECTION

Imaging agents from GE HealthCare
The Imaging Company for Imaging Experts

This evolution was important because **the osmolality of a contrast media may be associated with its cardiac and renal tolerability, as well as its impact on patient comfort.**²⁻⁶



Heritage shaping Healthcare worldwide

GE HealthCare has a distinguished heritage in contrast media development.^{7,8} We at Pharmaceutical Diagnostics have been supporting healthcare providers for over 150 years. Today, we're a global leader in diagnostics, with 110M+ doses of our imaging agents produced globally every year.⁹

VISIPAQUE™
(IODIXANOL) INJECTION

Imaging agents from GE HealthCare
The Imaging Company for Imaging Experts

VISIPAQUE™ (IODIXANOL) INJECTION

Imaging agents from GE HealthCare

The Imaging Company for Imaging Experts



Wide product offering
with **flexible options**

Gluten-free, latex-free
& Halal certified



Used in more than
100 countries

Over **30 years** of
clinical excellence



References: **1.** Jakobsen JA. Physiological effects of contrast media for use in multidetector row computed tomography. *Eur J Radio l.* 2007;62(Suppl.):S14-S25; **2.** Spencer CM, Goa KL. Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium. *Drugs.* 1996;52(6):899-927; **3.** Kerl JM, Nguyen SA, Lazarchick J, et al. Iodinated contrast media: effect of osmolarity and injection temperature on erythrocyte morphology in vitro. *Acta Radiol.* 2008;49(3):337-343; **4.** Katsanos K, Moutzouri A, Karnabatidis D, Siablis D, Athanassiou G. Influence of contrast media on red blood cell deformability. *Clin Hemorheol Microcirc.* 2008;39(1-4):87-91; **5.** McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. *J Am Coll Cardiol.* 2016;68(13):1465-1473; **6.** McCullough PA, Capasso P. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials. *BMC Med Imaging.* 2011;11:12; **7.** Widmark JM. Imaging-related medications: a class overview. *Proc (Bayl Univ Med Cent).* 2007; 20: 408-17; **8.** Greco A, McNamara MT, Lanthier P, Quay SC, Michelozzi G. Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine-phase II-III clinical trial. *Radiology.* 1990; 176: 451-6; **9.** GE HealthCare. This is Pharmaceutical Diagnostics. October 2023.

Please scan the QR code below to see approved indications and Important Safety Information for VISIPAQUE™ (IODIXANOL)



VISIPAQUE™
(IODIXANOL) INJECTION



GE HealthCare

Distributed in Canada by GE HealthCare

© 2024 GE HealthCare

Visipaque is a trademark of GE HealthCare.

GE is a trademark of General Electric Company used under trademark license.

JB01169CA/07-2024